SCHEMBL3928318

SCHEMBL3928318

CC(Cc1ccccc1)(NC(=O)c1ccc2ccccc2c1OCCOc1ccc(F)cc1)C(=O)O

nearest known ligand 0.67

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ CXCR2 P25025 12/20 0.67
▸ ITGB3 P05106 1/20 0.40
▸ ITGA2B P08514 1/20 0.40
▸ LMNA P02545 2/20 0.39
▸ MAPK1 P28482 1/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ NPSR1 Q6W5P4 1/20 0.39
▸ HDAC3 O15379 1/20 0.38
▸ HDAC4 P56524 1/20 0.38
▸ HDAC1 Q13547 1/20 0.38
▸ HDAC7 Q8WUI4 1/20 0.38
▸ HDAC2 Q92769 1/20 0.38
▸ HDAC10 Q969S8 1/20 0.38
▸ HDAC11 Q96DB2 1/20 0.38
▸ HDAC8 Q9BY41 1/20 0.38
▸ HDAC6 Q9UBN7 1/20 0.38
▸ HDAC9 Q9UKV0 1/20 0.38
▸ HDAC5 Q9UQL6 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3926566 0.90 CXCR2 (0.72) CXCR2LMNASMN1; SMN2HDAC3HDAC4
SCHEMBL3936425 0.87 CXCR2 (0.76) CXCR2LMNASMN1; SMN2HDAC3HDAC4
SCHEMBL3927181 0.84 CXCR2 (0.66) CXCR2LMNASMN1; SMN2NPSR1HDAC3
SCHEMBL3925368 0.83 CXCR2 (0.83) CXCR2LMNANPSR1HDAC3HDAC4
SCHEMBL3926644 0.83 CXCR2 (0.83) CXCR2LMNANPSR1HDAC3HDAC4
SCHEMBL3929169 0.83 CXCR2 (0.83) CXCR2LMNANPSR1HDAC3HDAC4
SCHEMBL3924566 0.81 CXCR2 (0.66) CXCR2LMNASMN1; SMN2HDAC3HDAC4
SCHEMBL3935092 0.81 CXCR2 (0.72) CXCR2LMNASMN1; SMN2HDAC3HDAC4
SCHEMBL3928733 0.81 CXCR2 (1.00) CXCR2LMNAHDAC3HDAC4HDAC1
SCHEMBL3926118 0.80 CXCR2 (0.74) CXCR2LMNAHDAC3HDAC4HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8501981-B2 CXCR2 inhibitors SANOFI (FR) 2013-08-06 — — US claimed
US-20090227625-A1 CXCR2 INHIBITORS SANOFI-AVENTIS (FR) 2009-09-10 — — US claimed
EP-2040688-A1 NEW CXCR2 INHIBITORS Sanofi-Aventis (FR) 2009-04-01 — — EP claimed
WO-2008000409-A1 NEW CXCR2 INHIBITORS SANOFI-AVENTIS (FR) 2008-01-03 — — WO claimed
US-8501981-B2 CXCR2 inhibitors SANOFI (FR) 2013-08-06 — — US disclosed
US-8501981-B2 CXCR2 inhibitors SANOFI (FR) 2013-08-06 — — US disclosed
US-8501981-B2 CXCR2 inhibitors SANOFI (FR) 2013-08-06 — — US disclosed
US-20090227625-A1 CXCR2 INHIBITORS SANOFI-AVENTIS (FR) 2009-09-10 — — US disclosed
US-20090227625-A1 CXCR2 INHIBITORS SANOFI-AVENTIS (FR) 2009-09-10 — — US disclosed
US-20090227625-A1 CXCR2 INHIBITORS SANOFI-AVENTIS (FR) 2009-09-10 — — US disclosed
EP-2040688-A1 NEW CXCR2 INHIBITORS Sanofi-Aventis (FR) 2009-04-01 — — EP disclosed
WO-2008000409-A1 NEW CXCR2 INHIBITORS SANOFI-AVENTIS (FR) 2008-01-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090227625-A1 CXCR2 INHIBITORS CXCR2, CXCR1, CXCR4 CXCR2 1/4885ITGB3 1349/4885ITGA2B 1069/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback